ArticleCureus2025
Testing the Immunomodulatory Effects of Probiotic Bacillus coagulans SNZ 1969® in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trial.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe immune system and the gastrointestinal tract are intricately linked. The intestinal barrier, microbiome, and immune system are in constant communication, shaping immune responses and maintaining homeostasis. Imbalances in the gut microbiome can affect the intestinal barrier and increase susceptibility to infections, along with a decline in immune function (both innate and adaptive immunity). Maintaining optimal immune function is crucial for protecting against infections and supporting overall health, particularly in populations that may be more vulnerable to seasonal respiratory and gastrointestinal infections. Probiotics, particularly spore-forming strains, demonstrate potential for improving natural killer (NK) cell function and mucosal immunity through gut-associated lymphoid tissue interactions. This study evaluated the immunomodulatory effects of
methodsThis randomized, double-blind, placebo-controlled clinical trial enrolled adults aged 60-65 years who were susceptible to seasonal infections. Participants were randomized 1:1 to receive either
resultsOf 60 enrolled participants, 50 completed the study (25 per group).
conclusions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.